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Ro 31-7549, on the Proliferation of Cultured Mouse 
Epidermal Keratinocytes 
Wendy B. Bollag, Janet Ducote, and Charles S. Harmon 
Preclinical Dermatology Research, Hoffmann-La Roche, Nutley, New Jersey U.S.A. 
We have investigated the effects ofRo 31-7549, a selective 
protein kinase C (PKC) inhibitor, on DNA synthesis and 
proliferation in two primary mouse epidermal keratinocyte 
culture systems. In differentiating keratinocytes incubated in 
medium containing 10% serum and high calcium (ap£roxi-
mately 0.5 mM), Ro 31-7549 blocked the inhibitory effect of 
the phorbol ester 12-0-tetradecanoyl-13-acetate (TPA) (a 
PKC activator) on keratinocyte DNA synthesis at 24 h [50% 
maximal response concentration (ECso) = 1 ,uM], consistent 
with inhibition of PKC-mediated differentiation. Continu-
ous treatment of the differentiative culture system with the 
PKC inhibitor resulted in a marked (fourfold) stimulation of 
[3H]thyrnidine incorporation at day 7 of exposure, with an 
ECso of 0.25 ,uM. The potencies of these effects of Ro 31-
7549 are comparable to that reported for inhibition ofTPA-
induced platelet 47-kD protein phosphorylation [50% inhibi-
tory concentration (ICso) = 4.4 ,uM]. The time course of 
Protein kinase C (PKe) , the phospholipid-dependent, cal-cium-sensitive, diacylglycerol (DAG) - activated pro-tein kinase described by Nishizuka (reviewed in [1 j), is known to regulate proliferation and differentiation in a variety of cell types . There are numerous data to support 
such a role for PKC in the regulation of keratinocyte growth and 
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Abbreviations: 
AMP: adenosine monophosphate 
BSA: bovine serum albumin 
DAG: diacylglycerol 
DMSO: dimethylsulfoxide 
ECso : 50% maximal response concentration 
FBS: fetal bovine serum 
ICso : 50% inhibitory concentration 
ITS: insulin, transferrin, and selenious acid 
ODC: ornithine decarboxylase 
PBS: phosphate-buffered saline 
PEN: phosphate, ethylenediaminetetraacetic acid, and sodium chloride 
PKC: protein kinase C ' 
SFKM: serum-free keratinocyte medium 
TGA: trans glutaminase 
TPA: 12-0-tetradecanoyl-phorbol-13-acctate 
[3H]thymidine incorporation indicated that Ro 31-7549 did 
not directly stimulate DNA synthesis but instead prevented 
the loss of proliferative capacity associated with continued 
culture in this medium. Maximal stimulation (2.6 times) of 
DNA synthesis was observed on day 4, whereas 0 N A synthe-
sis at day 1 was unaffected. In a highly proliferative culture 
system using serum-free medium containing 25 ,uM calcium, 
TPA dose-dependently inhibited proliferation with an ICso 
of approximately 0.3 nM. This antiproliferative effect of 
TPA was largely reversed by 0.1,uM Ro 31-7549. In the 
proliferative culture system, 0.75,uM Ro 31-7549 also es-
sentially reversed the inhibition of proliferation caused by 
switching to high (1.0 mM) calcium. These results suggest 
that the loss of proliferative capacity in differentiating epi-
dermal keratinocyte cultures may be mediated, at least in part, 
by PKC.] Invest DermatoI100:240-246, 1993 
differentiation. For example, PKC is a well-known cellular receptor 
for phorbol esters, which bind to and activate this enzyme [1]; in 
mouse skin in vivo phorbol esters are known tumor promoters [2,3]. 
In primary cultures of murine keratinocytes phorbol esters, such as 
12-0-tetradecanoyl-phorbol-13-acetate (TPA), elicit divergent re-
sponses of both proliferation and differentiation. Thus, TP A expo-
sure results in the induction of both ornithine decarboxylase (ODe) 
and trans glutaminase (TGA), markers of keratinocyte proliferation 
and differentiation, respectively [4-6]. TPA also acutely (24 h) in-
hibits DNA synthesis [7], due to the recruitment of a subpopulation 
of cells to a differentiated state [5,8]; the differentiated cells detach 
from the plate within 48 h and those remaining are resistant to the 
prodifferentiative effects of high calcium or a second TP A treat-
ment [5]. On the other hand, prolonged (2-3 d) TPA treatment 
results in a marked stimulation of keratinocyte DNA synthesis [7] . 
This biphasic response to TPA is also observed in villo [2,3]. Thus, 
using the pharmacologic agent TPA as a PKC activator, several 
investigators have obtained evidence to indicate the possible in-
volvement of PKC in the regulation of keratinocyte proliferation 
and differentiation. 
Further complicating the interpretation of such TP A effects is the 
fact that the compound elicits two nearly concurrent events: PKC 
activation and PKC down-regulation [1]. Several investigators have 
reported that TP A treatment induces a ral?id but incomplete PKC 
down-regulation in mouse keratinocytes 19,10], as in many other 
systems. The question remains, however, as to which TPA-elicited 
effects are mediated by PKC activation and which are the result of 
down-regulation. Nevertheless, comparisons of the kinetics ofPKC 
down-regulation do not resolve this issue for several reasons, in-
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Figure 1. Structure of the bisindolylmalcimide PKC inhibitor Ro 31-7549. 
eluding 1) the aforementioned ability ofTPA to cause both activa-
tion and down-regulation of PKC; 2) the fact that there is a time 
delay of unknown duration between early signal-transduction 
events and such complex processes as DNA synthesis, proliferation, 
and differentiation; and 3) the apparent inability ofTPA to-induce 
complete down-regulation [9,10J, because the percentage of PKC 
activity required for a cellular response is unknown. Due to these 
difficulties, it has become apparent that compounds that selectively 
inhibit PKC in intact cells are needed to determine the role of this 
enzyme in cellular processes [11]. 
Calcium is another keratinocyte regulator for which the role of 
PKC is unclear. Nevertheless, there is evidence to suggest that in 
this case also PKC activation and differentiation may be coupled: 
switching keratinocytes from low to physiologic extracellular cal-
cium concentrations elicits both differentiation [12] and the forma-
tion of diacylglycerol (DAG) [13,14]' the natural activator ofPKe. 
Similarly, the addition of exogenous phospholipase C (PLC) to 
primary mouse epidermal keratinocytes results in the formation of 
DAG; like TPA, exogenous PLC also induces TGA and ODC [4]. 
In addition, synthetic DAGs have been reported to promote modest 
differentiative responses [15]. Furthermore, Isseroff et at [15] have 
observed effects of high calcium on the subcellular distribution of 
PKe. Finally, inhibition of PKC activity, either by TPA-induced 
enzyme down-regulation or with the use of putative enzyme inhibi-
tors, has been shown to prevent the differentiative effect of high 
extracellular calcium concentrations [16] . On the other hand, these 
non-selective PKC inhibitors have also been reported both to mimic 
and prevent the effects of TPA, on for instance ODC and TGA 
induction [17 - 19]. Thus, although several lines of evidence indi-
cate that PKC is involved in the regulation ofkeratinocyte prolifera-
tion and differentiation, the exact role of this enzyme is unclear. 
Again, the utility of a selective PKC inhibitor is obvious. 
Recently, a series of bisindolylmaleimides has been shown to 
possess potent and selective inhibitory activity towards PKC in cell-
free assays, with markedly reduced potencies towards cyclic adeno-
sine monophosphate (AMP)-dependent and calcium/calmodulin-
dependent protein kinases [20]. In addition, these PKC inhibitors 
inhibit in cellular assays both TPA-induced 47 -kD protein phospho-
rylation in platelets and phorbol-ester- induced down-regulation of 
CD3 receptors in human T cells [20]' Furthermore, the bisindolyl-
maleimide PKC inhibitors have been used by several investigators 
to demonstrate the involvement ofPKC in such cellular responses as 
cerebellar long-term depression [21], the neutrophil respiratory 
burst [22] , fibrobl as t proliferation [11), and mast cell histamine re-
lease and phospholipase D activation [23] . In the present study we 
have used one such bisindolylmaleimide PKC inhibitor, Ro 31-
7549 (Fig 1), to investigate the role of PKC in the regulation of 
keratinocyte proliferation. 
MATERIALS AND METHODS 
Cell Isolation and Culture Mouse epidermal keratinocytes 
were prepared according to the method of Marcelo et at [24] with 
minor modifications. Briefly, whole skin from 2-d-old neonatal 
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CD-l mice was incubated at 4°C in HE PES [4-(2-hydroxyethyl)-I-
piperazine-ethanesulfonic acid]-buffered RPM I 1640 medium 
containing 0.25% trypsin overnight, followed by an approximate 
45-min incubation at 37°e. After mechanical separation of the 
epidermis from the dermis with forceps, keratinocytes were de-
tached and purified through a stepwise (12-20%) Ficoll gradient. 
Cells from the lower two layers were pooled, washed, and counted. 
For studies in a differentiative high-calcium, serum-containing me-
dium, cells were plated in 96- or 6-well plates (Corning, Park 
~idge, IL) at a density of 500,000 cells/cm2 and cultured overnight 
m RPMI 1640 medium containing 10% fetal bovine serum, 100 
units/ml penicillin, 100,ug/ml streptomycin, and 0.25 ,ug/ml fun-
glzone at 32°C. Cultures were then treated with medium contain-
ing the test compounds and were refed every 1- 3 d. 
For studies in proliferating cu ltures, cells were plated in six-well 
plates at a denSity of 25,000 cells/ cm2 in 10% fetal bovine serum-
containing RPMI 1640. Cells were allowed to adhere for 4 h in 
serum-containing medium after which time the cultures were 
~ashed with phosphate-b~ffered saline lacking calcium and magne-
SIUm (PBS) and refed With a serum-free keratinocyte medium 
(SFKM) according to Yada et at [25J with minor modifications. 
S~KM consisted of calcium-free ~lOdified Eagles' medium (Spe-
cI~lty Media, Lafayette, NJ) contalI1l11g 25 ,uM calcium,S ng/ml 
epidermal growth factor, 1 mM glutamine, 90,ug/ml bovine pitui-
tary extract,.ITS (5 ,ug/mll11sull11 + 5,ug/ml transferrin + 5 ng/ml 
sele?lO~s aCid), 0.05% bovl11e serum albumin (BSA), 100 units/ml 
pemclill11, 100 ,ug/ml streptomycin, and 0.25 ,ug/ml fungizone. 
Cells we~e I11cubated overmght at 37°C in the low-calcium, serum-
free medIUm and were subsequently treated with medium contain-
ing the test compounds; cells were refed every 1- 3 d. In some 
experiments ITS + (6.25 ,ug/ml transferrin + 6.25 ng/ml se-
lenious acid + 5.35 ,ug/mllinoleic acid + 0.125% BSA) was substi-
tuted for ITS and 0.05% BSA. 
M.e~sur.ement of~NA Synthes~s For measurement of[3HJthy-
mldme mcorporatlOn, cells were mcubated in differentiative 10% 
FBS-co~ta!ning n:edium .containing 5-10 ,uCi/ml [3H]thymidine 
for the mdlcated time penods. After labeling, cultures were washed 
with phosphate-buffered saline and incubated with 1 % trypsin at 
3r e. Detached cells were collected onto filters using an automated 
cell harvester, washe?, and counted in a liquid scintillation spec-
~rometer. For determmatlOn of DNA spcific radioactivity, trypsin-
Ized cells were washed thoroughly with saline (0.9% NaCI + 
50 mM phosphate, pH 7.4) to remove the enzyme and were lysed in 
~EN buffer (50 mM phosphate + 2 mM ethylenediaminetetraace-
tiC aCid + ~ M. NaCI, PI! 7.4) by sonication. Aliquots were taken 
for determmatlOn of radIOaCtiVity and measurement of DNA con-
tent using the fluorescent dye, Hoechst 33258, and calf thymus 
DNA (Clonetech Laboratories, Palo Alto, CA) as standard [26J. 
Determination of Cell Number Cells were washed with PBS 
and wer~ in.c~bated at 37°C with 0.5% trypsin to detach cells. 
Trypsl11 mlubltor was then added and the cells were triturated 
through an 18-gauge I?eedle to generate a single-cell suspension. An 
aliquot of thiS SllspenSlOn was added to 10 ml saline and cell number 
was determined using an electronic particle counter (Coulter Elec-
tronics, Hialeah, FL). 
Materials TPA (CCR Acquisition Corporation, Edina, MN) was 
a generous gift of Dr. A. Wood. [3H]Thymidine was purchased 
fr?m ICN (Irvl11e, CA). Hoechst 33258 was obtained from Poly-
sCiences (Warrl11gton, PA); Ficoll from Pharmacia (Piscataway, 
NJ); and bovine pituitary extract (P-Neurext) from Upstate Bio-
technolog~ (Lake Placid, NY). ITS and ITS + were purchased from 
Collaborative Research (Bedford, MA); trypsin and epidermal 
growth factor from Gibco (Grand Island, NY); RPMI 1640, FBS, 
glutamine, HEPES, and antibiotics from Hazleton (Lenexa, KS); 
and trypsin inhibitor, dimethylsulfoxide and bovine serum albumin 
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Figure 2. Ro 31-7549 reversed the inhibitory effect of an acute (24-h) exposure to TPA without itself affecting pH)thymidine incorporation into primary 
mouse epidermal keratinocytes_ A) Cells in the differentiative high-calcium, serum-containing medium were treated for 30 min with various concentrations of 
Ro 31-7549 prior to exposure to IIJM TPA for 24 h in the continued presence of the PKC inhibitor. pH)Thymidine incorporation was then determined after 
a 6-h labeling period. Data points are the means ± SEM (n = 4) of a representative experiment with control values (100 ± 10%) of 1236 ± 149 cpm/well 
(0.32 cm2); 'p :s 0.05, "p :s 0.005 versus control;·p:S 0.05, -p :s 0.005 versus TPA alone_ B) Cells in the differcntiative high-calcium, serum-containing 
medium were treated for 24 h with various concentrations ofRo 31-7549 and [3H)thymidine incorporation was determined after a 6-h labeling period. Data 
points are the means (n = 4) ± SEM of a representative experiment with control values (100 ± 4%, n = 8) of 2717 ± 110 cpm/well (0.32 cm2); 'p S; 0.05, 
" p :s 0.0005 versus control. 
(fatty acid free) from Sigma (St_ Louis, MO). All other materials 
were of reagent grade. 
RESULTS 
Ro 31-7549 has previously been demonstrated to potently inhibit 
PKC both in cell-free assays and in intact platelets and T cells in situ 
[20]- The ability ofRo 31-7549 to inhibit PKC activity in primary 
murine epidermal keratinocytes was investigated using the PKC 
activator TPA to initiate PKC-mediated cellular responses. Kerati-
nocytes cultured in the differentiative high-calcium, serum-con-
taining medium and pre-treated with various concentrations of Ro 
31-7549, were exposed to 1IJM TPA for 24 h in the continued 
presence of the PKC inhibitor, and [3H]thymidine incorporation 
was measured. As illustrated in Fig 2A, TPA inhibited DNA synthe-
sis by approximately 60%. Ro 31-7549 dose-dependently blocked 
this inhibition with a 50% maximal response concentration (ECso) 
of about 111M. At a concentration of 2.5 11M, Ro 31-7549 almost 
completely reversed the inhibitory effect ofTPA on [3H]thymidine 
incorporation (Fig 2A), indicating that Ro 31 -7549 inhibits kerati-
nocyte PKC. In Fig 2B is shown the effect ofRo 31-7549 alone on 
[3H]thymidine incorporation. At concentrations of Ro 31-7549 less 
than or equal to 2_5 11M, the PKC inhibitor alone had little or no 
effect on DNA synthesis after a 24-h exposure. At higher concen-
trations (> 2_5 11M) , Ro 31-7549 inhibited [3H]thymidine incorpo-
ration, likely as a result of cytotoxicity because protein synthesis 
decreased concomitantly (data not shown) . Taken together, the 
results shown in Fig 2A,B suggest that the reversal of the TPA 
inhibitory effect is the result of an inhibition of a PKC-mediated 
loss of proliferative capacity, rather than a direct enhancement of 
cell proliferation. 
We then examined the effect of long-term exposure to various 
concentrations of Ro 31-7549 on cell growth . Primary keratino-
cytes cultured in the differentiative high-calcium, serum-contain-
ing medium were treated for 7 d with various concentrations ofRo 
31-7549, and [3H]thymidine incorporation was determined. At 
lower concentrations (,.;;;5I1M) Ro 31-7549 alone dose-depen-
dently stimulated (3HJthymidine incorporation with an ECso of 
approximately 0.25 11M (Fig 3). A maximal increase in radio label of 
fourfold over control values was observed at a dose of 2.5 11M Ro 
31-7549; in separate experiments a mean ECso of 0 .6 11M and a 
mean maximal stimulation of 2.6 times were obtained. Doses 
greater than 5 11M again inhibited D N A synthesis, presumably due 
to cytotoxicity as measured by a concomitant fall in protein syn-
thetic rates (data not shown). 
The time course of the stimulatory effect ofRo 31-7549 on DNA 
synthesis was subsequently determined. Cells in the differentiative 
high-calcium, serum-containing medium were treated for various 
time periods with 211M Ro 31 -7549 and DNA synthesis was mea-
sured. As shown in Fig 4, there was an inverse correlation between 
proliferative activity in control cultures (i.e., rates of[3H]thymidine 
incorporation [Fig 4A] and DNA specific activity [Fig 4BJ) and the 
extent of the stimulation of DNA synthesis elicited by Ro 31-7549. 
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Figure 3. Ro 31-7549 stimulated [3H)thymidine incorporation into pri-
mary mouse epidermal keratinocytes at day 7 . Cells in the differentiative 
high-calcium, serum-containing medium were treated for 7 d with various 
concentrations ofRo 31-7549 and [3H)thymidine incorporation was deter-
mined after a 19-h labeling period. Data points are the means (n = 4) ± SEM 
of a representative experiment with control values (100 ± 3%) of29,238 ± 
817 cpm/well (0.32 cm2); 'p:S 0.025, "p:S 0.0005 versus control. 
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Figure 4. Ro 31-7549 maintained DNA synthesis in differentiating pri-
mary mouse epidermal keratinocytes. Cells in the differentiative high-cal-
cium, serum-containing medium were treated for various time periods with 
2 11M Ro 31-7549 and (A) [3HJthymidine incorporation (dpm/well) and (B) 
DNA specific radioactiviry (dpm/Jig DNA) were determined after a 4-h 
labeling period. Solid squares, [3HJthymidine incorporation (A) or DNA-spe-
cific activiry (B) in the absence of Ro 31-7549; Opetl circles, DNA-specific 
activiry in the presence of 2 11M Ro 31-7549, expressed as percent of the 
control values. Data points are the means (± SEM) of at least three samples 
from a single experiment; 'p :5 0.05, "p :5 0.005 versus control. 
Thus, during the period of relatively high proliferative activity 
following plating of the cells (days 1-2 of culture), Ro 31-7549 ~ad 
little or no effect on DNA synthesis as measured by [3H]thymldme 
incorporation. As proliferation declined over days 3 -4 of culture, 
Ro 31-7549 progressively enhanced [3H]thymidine incorporatt~n/ 
DNA synthesis. A similar, inverse relationship was observed dunng 
a second (smaller) peak of DNA synthesis at days 5-6 and the 
subsequent decline over day 7. A maximal, 2.6-times stimulation of 
DNA synthesis by Ro 31-7549 was obtained on day 4. A second 
experiment gave qualitatively similar results, although control 
[3H]thymidine incorporation declined more slowly and no secon.d 
peak of DNA synthesis was observed (data not shown). In this 
experiment also stimulation of [3H]thymidine incorp~ration ~y Ro 
31-7549 was minimal during the period of relatively high prohfera-
tive activity; however, as control [3H]thymidine incorporation d~­
dined, the Ro 31-7549-induced enhancement of DNA synt~eS1S 
progressively increased to reach a maximal stimulation of2.4-ttmes 
over control on day 7 (data not shown). Thus, the results of Figs 3 
and 4 suggest that with continued culture in a differentiative high-
calcium, serum-containing medium, there is a time-dependent 
PKC-mediated loss of proliferative capacity that is likely the result 
ofPKC activity and can be prevented by Ro 31-7549. 
Recently, a serum-free system for the culture of primary mouse 
epidermal keratinocytes has been developed (see Materials and Meth-
ods). This medium (SFKM) supports good cell growth such that 
keratinocytes can be plated at low densities and their proliferation 
monitored directly by cell counting as they approach confluence 
(after approximately a week, data not shown). We have used this 
culture system to examine the effects ofTPA, a known antiprolifera-
tive agent, on keratinocyte growth as measured by changes in cell 
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number. Keratinocytes cultured in SFKM were treated with various 
concentrations of TPA and cell number was determined initially 
and after 4 d of treatment. In the absence of TP A, cell number 
increased by 2.6-times from day zero (time of addition of TPA). 
TPA dose-dependently inhibited proliferation with a 50% inhibi-
tory concentration (ICso) of approximately 0.3 nM (Fig 5) . Maxi-
mal inhibition of74% was observed at a concentrationofl0 nM. In 
a second experiment similar results were obtained although TPA 
exhibited a somewhat lower potency (ICso of about 1.5 nM). Thus, 
TPA potently inhibits proliferation of primary keratinocytes cul-
tured in this serum-free medium. 
. TP A also elicited a characteristic rapid change in keratinocyte 
morphology, from the appearance of control cells illustrated in Fig 
6A to, after a 6-h treatment, the "dendritic" morphology shown in 
Fig 6B. This morphologic change occurred quite rapidly: initial 
effects were observed after as few as 3 h of exposure to TP A, but the 
response was enhanced with longer periods (up to 4 d) of exposure 
(data not shown). As shown in Fig 6C, 0.5,11M Ro 31-7549 abro-
gated this TPA-induced morphologic change. The ability of Ro 
31-7549 to block this characteristic shape change was dose depen-
dent in the range 0.1-1.0,l1M (data not shown), and incubation 
with Ro 31-7549 alone had little or no effect on keratinocyte ap-
pearance (Fig 6D). These results provide additional evidence that 
Ro 31-7549 is able to inhibit keratinocyte PKC. 
We next examined the ::bility of Ro 31-7549 to prevent the 
antiproliferative effect of TP A in keratinocytes grown in SFKM. 
Highly proliferative cells cultured in SFKM were switched to me-
dium containing 10 nM TP A and various concentrations of Ro 
31-7549, and cell number was determined after 4 d of treatment. As 
illustrated in Fig 7,10 nM TPA reduced cell number by 45%, from 
a control value of22,732 ± 768 cells/cm2 (representing a 3.1-times 
increase in cell number from day 0) to 12,467 ± 185 cells/cm2• 
This reduction in cell number was partially prevented by 0.1 ,11M Ro 
31-7549: in the presence ofTPA, 0.1 ,11M Ro 31-7549 returned cell 
number to 86% of the control value. In several additional experi-
ments, an average TPA-elicited decrease of 41 ± 3% was returned 
to 87 ± 6% of the control cell number by concentrations of the 
PKC inhibitor ranging from 0.1 to 0.5,11M. Thus, Ro 31-7549 
blocked, at least partially, the TPA-elicited inhibition of growth in 
this proliferative culture system. 
Data from several laboratories suggest that PKC may also be 
in~olved in the .antiproliferative effect of high calcium in primary 
epidermal keratmocytes [13 -16, 27 -30]. We therefore examined 
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Figure 5. TPA dose-dependently inhibited proliferation of primary mouse 
epidermal keratinocytes. Highly proliferative cells cultured in the low-cal-
cium, SFKM were switched to medium containing various concentrations of 
TPA and 0.1 % dimethylsulfoxide. Cell number was determined after 4 d of 
treatment and represented a 2.6-times increase from day a (p:5 0.0005 
versus control cell number on day 4). Data points are the means (control, 
n = 5; TPA, n = 3) ± SEM of a representative experiment; 'p:5 0.005 
versus control. 
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Figure 6. Ro 31-7549 prevents the characteristic "dendritic" morphologic changes elicited by TPA. Highly proliferative cells, incubated in SFKM in the absence 
(A ,D) or presence (B,C) of 10 nM TPA-with (C,D) or.without (A,B) 0.5 jlM Ro 31-7549 wer~ photographed after 6.-h <;xposure to the agents. All samples 
contained 0.1 % dimethylsulfoxIde. Arrows, representatIve TPA-eltclted "dendrlttc" morphologIc changes, whIch are IIllubtted by Ro 31-7549. Bar, 10 jlm. 
the abi lity of Ro 31-7549 to prevent the antiproliferative effect of 
high (1 rnM) calcium. Highly proliferative cells cultured in SFKM 
were switched to medium containing 1.0 rnM calcium and various 
concentrations of Ro 31-7549, and cell number was determined 
after 4 d of treatment. In low (25 ,LiM) -calcium (control) and high 
(1 mM) -calcium cultures, the increase in cell number from day 0 
was 3.7 times and 2.7 times, respectively. Thus, switching to high 
calcium resulted in an approximately 30% inhibition in culture 
growth over the 4-d period. Figure 8 shows that Ro 31-7549 dose-
dependently blocked this growth-inhibitory effect of calcium such 
that at a concentration of 0.75,LiM cell number was returned to 
control levels. This reversal occurred despite the fact that cell num-
ber in the presence of 0.75,LiM Ro 31-7549 alone was somewhat 
reduced (79% of the control value, data not shown). This result 
suggests that calcium-induced growth inhibition in proliferating 
keratinocytes may be mediated, at least in part, by PKC. 
DISCUSSION 
Several investigators have attempted to determine the r:ole of PKC 
in the regulation of keratinocyte growth and differentiation using 
reported PKC inhibitors, such as H-7 [1-(5-isoquinolinyl-sul-
fony l)-2-methylpiperazineJ, sphingosine, staurosporine, and bryos-
tatin 1, with occasionally unexpected results. Certain inhibitors 
block some but not all PKC-mediated responses, whereas others 
may only partially inhibit such responses [18]. Still others behave in 
keratinocytes as partial agonists/antagonists, J?reventing some and 
mimicking other PKC-mediated effects [19J. And finally some 
"PKC inhibitors" act in these cells as PKC agonists, eliciting in 
some cases a greater response than the PKC activator TPA [17]. 
Clearly, none of these PKC "inhibitors" is ideal for an investigation 
of the role of the enzyme in a cellular response; we, therefore, have 
used the selective PKC inhibitor Ro 31-7549 to study the possible 
involvement ofPKC in the regulation ofkeratinocyte proliferation. 
The abi lity ofRo 31-7549 to block the effect ofTPAon keratino-
cyte [3H]thymidine incorporation (Fig 2A), morphology (Fig 6), 
and proliferation (Fig 7) indicates that the compound is able to 
inhibit keratinocyte PKC. This result is not unexpected, because Ro 
31-7837, in addition to inhibiting PKC potently and selectively in 
cell-free assays, has previously been shown to prevent TPA-induced 
47-kD protein phosphorylation in intact platelets and CD3-recep-
tor down-regulation in whole human T cells [20]. Furthermore, a 
close structural analog ofRo 31-7549, GF 109203X, has been dem-
onstrated to inhibit several PKC-mediated responses [11]. Thus, 
these bisindolylmaleimides are able to potently inhibit PKC activity 
both in cellular and cell-free assay systems and to block responses to 
the phorbol-ester PKC activators. Furthermore, the failure of Ro 
31-7549 alone to increase (3H]thymidine incorporation (Fig 2B) or 
cell number (data not shown) suggests that the compound did not 
stimulate DNA synthesis or proliferation directly but rather re-
versed the TPA-induced inhibition. Thus, our results suggest that 
inhibition of keratinocyte PKC maintains cellular proliferation. 
The interpretation that PKC plays a role in the loss of prolifera-
tive capacity of cultured keratinocytes is further supported by the 
time course of the Ro 31-7549 - elicited increase in DNA synthesis 
(Fig 4). On those days when control cultures were rapidly synthesiz-
ing DNA, the PKC inhibitor induced no or only small increases in 
[3H]thymidine incorporation and DNA-specific radioactivity, in 
comparison to the marked stimulatory effect ofRo 31-7549 on cells 
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Figure 7. Ro 31-7549 partially ~eversed the TPA-induce.d inhibition of 
proliferation of primary mouse epidermal kera~lIlocytes. Highly pr~hfera­
tive cells in SFK.M were pretreated for 30 m1l1 with vanous concentrations of 
Ro 31-7549 prior to treatment with 10 nM TP~ in the continued presence 
of the PKC inhibitor. Cell number was determllled after 4 d of treatment 
and represented a 3.1-times increase from day 0 (p:S 0.0005 versus co~ro~ 
cell number on day 4). Data po liltS are the means (control and TPA, n - 6, 
Ro 31-7549, n = 3) ± SEM of a representative experiment; .p ~ ?05, 
.op :S 0.005 versus control value; .p :S 0.05 versus 10 nM T~ A. Addltlonal 
experiments in which TPA and Ro 31-7549 were added simultaneously 
gave similar results. 
that exhibited minimal DNA synthetic activity. Note that control 
cells demonstrated a time course of DNA synthesis similar to those 
reported previously in a nearly identical culture system [24,30]. 
Ro 31-7549 at several concentrations significantly stimulated 
[3H]thymidine ~ncorporation ~fter 7.d of treatment in a differenta-
tive medium, wIth maxImal stImulatIOn seen at 2.5 ,u~ and an ECso 
of approximately 0:25 - 0.6 ,uM (~ig .3~ . This Fotenc):' IS greater than 
that obtained preVIOusly for the mhlbltIon 0 TPA-mduced 47-kD 
protein phosphorylation in platelets (ICso of 4.4 ,uM) [~O] .. ~~w­
ever this value is consistent with ICso values reported for mhlbltlOn 
by GF 109203X (the Ro 31-7549 analog) ofPKC-mediated cel~u.lar 
responses (ICsos of 0.2 .to ~pproxim~tely 1.5 f.!M) [11] . Other blsm-
dolylmaleimide PKC mhlbltors wIth ICsos m the range of 0.7 to 
1.2,uM in the platelet 47 -kD protem phosphoryl~tIon assa>: also 
stimulated (3H]thymidine incorporation at day. 7 wIth pote~c~es of 
0.6 to 1.5 ,uM.· Therefore, it is likely that the stImulatory a.ctlvlo/.of 
Ro 31-7549 on [3H]thymidine incorporation is related to ItS abIlIty 
to inhibit PKC. 
The selectivity ofRo 31-7549 also would suggest that the agent is 
functioning through inhibition ofPKC activity. In ill vitro assay.s ~o 
31-7549 demonstrates an approximate 60- and 200 times selectlVlty 
for PKC over cyclic AMP-dependent protein kinase (PKA) and 
calcium/calmodulin-dependent protein kinase, respectIvely [20]. 
The analog (GF 109203X) has also been shown to be highly selec-
tive for PKC both in cellular and cell-free assays [11] . Therefore, th.e 
ability of Ro 31-?549 to ~ti~u!ate [3H].t~ymidi~e ~ncorporat~on ~s 
likely a result of Its PKC mhlbltory actiVity. TillS mterpretatlOn IS 
also supported by the ability of the compound to block effect~ of 
TPA (Figs 2, 6, and 7), which is known to be a potent PKC activa-
tor. At higher concentrations, however, Ro 31-!54? would be pre-
dicted to inhibit many, if not all, cellular protem kmases; thus, the 
cytotoxicity exhibited by Ro 31-7549 at high doses (approxImately 
2 .5 to 5 ,uM and above) is not unexpected. Nevertheless, because the 
primary effect we observed in this study was a sti~~la~io? of DNA 
synthesis and proliferation, the issue of cytOtOXICity IS Irrelevant. 
• c. S. Harmon, J. Ducote, and D. Lutz (unpublished observations). 
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Figure 8. Ro 31-7549 reversed the calcium-induced inhibition of prolifera-
tion of primary mouse epidermal keratinocytes. Highly proliferative cells 
cultured in the low-calcium, serum-free medium were switched to medium 
containing 1.0 mM calcium and various concentrations ofRo 31-7549. Cell 
number was determined after 4 d of treatment and represented a 3.7 -times 
increase from day 0 (p :s 0.0005 versus control cell number on day 4). Data 
points represent the means ± SEM of at least six samples from two separate 
experiments; . p:S 0.005 versus control value; .p :S 0.05 versus 1.0 mM 
calcium . 
T aken together, our results thus suggest that continued culture in a 
differentiative high-calcium, serum-containing medium results in a 
time-dependent PKC-mediated loss of proliferative capacity which 
is inhibited by Ro 31-7549. 
Our data suggest, therefore, that in keratinocytes PKC activation 
may playa role in a loss of proliferative potential, because blocking 
the activity of this enzyme stimulates proliferation. Paradoxically, 
the PKC-activating phorbol esters are also tumor promoters and 
prolonged exposure causes epidermal hyperplasia illl/ivD [2,3]. How-
ever, in addition to their ability to activate PKC, with continual 
exposure phorbol esters can also cause the down-regulation ofPKC 
and depletion of its activity [1 ,9,1 0,3 1]. In melanocytes, Brooks et al 
[32] have correlated phorbol ester-induced proliferation with 
down-regulation, and not transient activation, of PKC. Thus, the 
ability of phorbol esters to stimulate keratinocyte proliferation with 
chronic treatment may be related to their ability to cause down-reg-
ulation of PKC. This interpretation is further supported by the 
study of Hansen et al [33] who demonstrated that only those regi-
mens of treatment with TPA or sll-l,2-didecanoylglycerol that in-
duce PKC down-regulation also result in epidermal hyperplasia. It 
is not clear whether inhibiting PKC activity also inhibits down-reg-
ulation of the enzyme [34,35]. Thus, further investigation is re-
quired to determine the effect of PKC inhibitors on down-regula-
tion and tumor promotion. 
The results presented here also suggest that PKC may be involved 
in the calcium-induced growth inhibition of keratinocytes (Fig 8) . 
Such involvement is consistent with previous findings that high 
extracellular calcium concentrations induce phosphoinositide turn-
over and DAG production [1,9,10,31], events that usually result in 
PKC activation. Further support is provided by the observation that 
calcium induces subcellular redistribution ofPKC [15]. Dlugosz et 
al [16] have reported that bryostatin 1 treatment and TPA-induced 
down-regulation of PKC inhibit calcium-induced differentiation, 
again suggesting a role for PKC in the regulation of keratinocyte 
growth and differentiation. N evertheless, the lack of detectable 
PKC activation in Balb/MK cells exposed to high calcium [14] 
argues against an involvement ofPKC in calcium-induced diffe~en­
tiation; however, it should be noted that this cell line differentIates 
poorly relative to primary cultures of Balb/c keratinocytes [36] . 
Thus, although further study is necessary, it seems likely that PKC 
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may play some role in calcium-induced regulation of growth and 
differentiation. 
In this study we have demonstrated that the PKC inhibitor Ro 
31-7549 prevented the PKC-mediated inhibition of DNA synthesis 
elicited by acute exposure to the phorbol ester tumor promoter, 
TP A. Furthermore, in cells cultured for several days in a differentia-
tive high-calcium, serum-containing medium, Ro 31-7549 dose-
dependently stimulated DNA synthesis with an ECso of approxi-
mately 0.6 11M. The time course of DNA synthesis in cells cultured 
in the differentiative medium indicated that Ro 31-7549 did not 
directly stimulate DNA synthesis but instead maintained [3H]thy-
midine incorporation at elevated levels. Finally, in proliferating 
cells cultured in a serum-free medium, Ro 31-7549 prevented both 
calcium- and TPA-induced inhibition of proliferation. Thus, our 
results suggest that cells cultured with agents which promote dif-
ferentiation suffer a gradual loss of proliferative capacity which may 
be mediated, at least in part, by protein kinase C. 
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